OHIO — U.S. Customs and Border Protection (CBP) officers at the Port of Cincinnati have intercepted several shipments of unapproved weight-loss medications in recent months, including drugs like Ozempic, Wegovy, and Trulicity.
These drugs were found to violate federal regulations and pose potential health risks.
The most recent seizures occurred in October. On October 5, officers inspected a shipment labeled as a “cosmetic weight loss product,” which contained Mounjaro injectable pens in various dosages (2.5mg, 5mg, and 7mg).
The shipment, originating from a pharmacy in the United Kingdom, was addressed to a residence in Ohio.
It was seized for violating the Federal Food, Drug, and Cosmetic Act (FDCA).
On October 14, another shipment arrived from Hong Kong, containing 20 vials of 10 mg Semaglutide and 150 vials of 30 mg Tirzepatide, with an estimated domestic value of $45,450.
This package was also destined for Ohio and was seized by CBP officers.
Imported drugs must meet the U.S. Food and Drug Administration’s (FDA) standards for quality, safety, and effectiveness.
However, most online pharmacies do not comply with these standards, placing consumers at risk.
The drugs seized may contain unknown ingredients, ineffective dosages, or cause adverse side effects.
CBP is urging consumers to be cautious when purchasing medication from unverified sources, as these products can present serious health risks.
